BioNTech Appoints Kylie Jimenez as Chief People Officer to Management Board
BioNTech SE announced today that the Supervisory Board has appointed Kylie Jimenez to the Management Board as Chief People Officer (“CPO”) effective March 1, 2026. The appointment is in line with strategy to become a multi-product oncology company by 2030 and underscores the importance of its global, highly skilled workforce in achieving this objective. In the newly created Management Board role, Kylie Jimenez will be responsible for shaping and leading people strategy and its execution in alignment with the Company’s priorities and business goals. She will focus on attracting, developing and retaining talents and strengthening an inclusive culture. She will be based in the Company’s headquarters in Mainz, Germany.
Kylie Jimenez is a seasoned global HR executive with more than 20 years of experience in shaping and scaling international organizations. She will join from the international manufacturing company Georg Fischer where she currently serves as global Chief Human Resources Officer (“CHRO”). Her previous experience includes human resources executive roles at the multinational automotive manufacturing company Toyota as well as different HR expert roles at Johnson & Johnson and General Mills.
Kylie Jimenez has a strong track record of developing sustainable people strategies and executing them into business outcomes. During her career, she has guided global enterprises through several transformation programs, aligning global strategic priorities with regional business needs. This includes the shift from a country-based structure to a centralized model for more than 40 countries as well as the development and implementation of several new HR operating models to support performance, inclusion, and enterprise agility.
“We are pleased to welcome Kylie Jimenez to BioNTech’s Management Board. Her extensive international experience in human resources and organizational leadership will further build on the successful track-record of the Company and help navigate BioNTech through an exciting phase,” said Helmut Jeggle, Chairman of the Supervisory Board of BioNTech. “Kylie Jimenez’s appointment reflects the importance of a global people strategy and its local execution to drive BioNTech’s long-term objectives. Further, it reinforces the Company’s commitment to operational excellence, aimed at expanding long-term value for shareholders, employees and patients alike.”
“I am honored to join BioNTech and contribute to its exciting journey,” said Kylie Jimenez, designated Chief People Officer at BioNTech. “Throughout my career, I have focused on shaping people strategies that drive deep engagement, simplify organizational structures and foster an environment that enables teams to thrive. BioNTech’s unique culture and its highly qualified employees are the foundation of its success, and I look forward to collaborating with my future colleagues on the Management Board and the teams around the globe to support the Company in realizing its mission.”
Kylie Jimenez holds citizenship in Canada, Spain, and Australia, and a bachelor’s degree from the University of Waterloo, Ontario.
A photo of Kylie Jimenez (© BioNTech SE, 2026) is available for download in BioNTech’s newsroom.
About BioNTech
Biopharmaceutical New Technologies is a global next generation immunotherapy company pioneering novel investigative therapies for cancer and other serious diseases. BioNTech exploits a wide array of computational discovery and therapeutic modalities with the intent of rapid development of novel biopharmaceuticals. Its diversified portfolio of oncology product candidates aiming to address the full continuum of cancer includes mRNA cancer immunotherapies, next-generation immunomodulators and targeted therapies such as antibody-drug conjugates (ADCs) and innovative chimeric antigen receptor (CAR) T cell therapies.
Based on its deep expertise in mRNA development and in-house manufacturing capabilities, BioNTech and its collaborators are researching and developing multiple mRNA vaccine candidates for a range of infectious diseases alongside its diverse oncology pipeline. has established a broad set of relationships with multiple global and specialized pharmaceutical collaborators, including Bristol Myers Squibb, Duality Biologics, Fosun Pharma, Genentech, a member of the Roche Group, Genmab, MediLink, OncoC4, Pfizer and Regeneron.
Source Link: https://www.biontech.com/
